Mueller, Roman-Ulrich, Messchendorp, A. Lianne, Birn, Henrik, Capasso, Giovambattista ORCID: 0000-0003-3469-8614, Cornec-Le Gall, Emilie, Devuyst, Olivier ORCID: 0000-0003-3744-4767, van Eerde, Albertien, Guirchoun, Patrick, Harris, Tess, Hoorn, Ewout J., Knoers, Nine V. A. M., Korst, Uwe, Mekahli, Djalila, Le Meur, Yannick, Nijenhuis, Tom, Ong, Albert C. M., Sayer, John A., Schaefer, Franz, Servais, Aude, Tesar, Vladimir, Torra, Roser, Walsh, Stephen B. and Gansevoort, Ron T. . An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. Nephrol. Dial. Transplant.. OXFORD: OXFORD UNIV PRESS. ISSN 1460-2385

Full text not available from this repository.

Abstract

Approval of the vasopressin V2 receptor antagonist tolvaptan-based on the landmark TEMPO 3:4 trial-marked a transformation in the management of autosomal dominant polycystic kidney disease (ADPKD). This development has advanced patient care in ADPKD from general measures to prevent progression of chronic kidney disease to targeting disease-specific mechanisms. However, considering the long-term nature of this treatment, as well as potential side effects, evidence-based approaches to initiate treatment only in patients with rapidly progressing disease are crucial. In 2016, the position statement issued by the European Renal Association (ERA) was the first society-based recommendation on the use of tolvaptan and has served as a widely used decision-making tool for nephrologists. Since then, considerable practical experience regarding the use of tolvaptan in ADPKD has accumulated. More importantly, additional data from REPRISE, a second randomized clinical trial (RCT) examining the use of tolvaptan in later-stage disease, have added important evidence to the field, as have post hoc studies of these RCTs. To incorporate this new knowledge, we provide an updated algorithm to guide patient selection for treatment with tolvaptan and add practical advice for its use.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Mueller, Roman-UlrichUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Messchendorp, A. LianneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Birn, HenrikUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Capasso, GiovambattistaUNSPECIFIEDorcid.org/0000-0003-3469-8614UNSPECIFIED
Cornec-Le Gall, EmilieUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Devuyst, OlivierUNSPECIFIEDorcid.org/0000-0003-3744-4767UNSPECIFIED
van Eerde, AlbertienUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Guirchoun, PatrickUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Harris, TessUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hoorn, Ewout J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Knoers, Nine V. A. M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Korst, UweUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mekahli, DjalilaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Le Meur, YannickUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nijenhuis, TomUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ong, Albert C. M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sayer, John A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schaefer, FranzUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Servais, AudeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tesar, VladimirUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Torra, RoserUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Walsh, Stephen B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gansevoort, Ron T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-606691
DOI: 10.1093/ndt/gfab312
Journal or Publication Title: Nephrol. Dial. Transplant.
Publisher: OXFORD UNIV PRESS
Place of Publication: OXFORD
ISSN: 1460-2385
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
PROGRESSION; ANTAGONIST; BIOMARKERS; MANAGEMENT; VESICLES; EQUATION; TRIALS; SALTMultiple languages
Transplantation; Urology & NephrologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/60669

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item